推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733，021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

Guidelines for Immune Thrombocytopenia

D Provan, AC Newland… - New England Journal of …, 2011 - Mass Medical Soc
The Authors Reply: Wagle and Aragon-Ching both make the point that there were alternative
explanations for the reductions in the use of ADT that we noted other than financial
incentive. We agree and acknowledged a number of other po- tential contributing factors ...
Cited by 1 - Related articles - All 2 versions

Fever with thrombocytopenia associated with a novel bunyavirus in China

XJ Yu, MF Liang, SY Zhang, Y Liu… - … England Journal of …, 2011 - Mass Medical Soc
Xue-Jie Yu, MD, Ph.D., Mi-Fang Liang, MD, Shou-Yin Zhang, Ph.D.,* Yan Liu, MD, Jian-Dong
Li, Ph.D., Yu-Lan Sun, MD, Lihong Zhang MD, Quan-Fu Zhang, B.Sc., Vsevolod L. Popov,
Ph.D., Chuan Li, B.Sc., Jing Qu, B.Sc., Qun Li, MD, Yan-Ping Zhang, MD, Rong Hai, MD, ...
Cited by 9 - Related articles - All 5 versions

Antenatal interventions for fetomaternal alloimmune thrombocytopenia.

R Rayment, SJ Brunskill, PW Soothill… - … of systematic reviews …, 2011 - ncbi.nlm.nih.gov
BACKGROUND: Fetomaternal alloimmune thrombocytopenia results from the formation of antibodies
by the mother which are directed against a fetal platelet alloantigen inherited from the father.
The resulting fetal thrombocytopenia (reduced platelet numbers) may cause bleeding, ...
Cited by 2 - Related articles

CalDAG-GEFI deficiency protects mice in a novel model of Fc {gamma} RIIA-mediated thrombosis and thrombocytopenia.

M Stolla, L Stefanini, P André, TD Ouellette… - Blood, 2011 - ncbi.nlm.nih.gov
Platelet activation via Fcγ receptor IIA (FcγRIIA) is a critical event in immune-mediated thrombocytopenia
and thrombosis syndromes (ITT). We recently identified signaling by the guanine nucleotide
exchange factor CalDAG-GEFI and the ADP receptor P2Y12 as independent pathways ...

DEVELOPMENT OF C-REACTIVE PROTEIN MUTANT WITH IMPROVED THERAPEUTIC BENEFIT IN IMMUNE THROMBOCYTOPENIA AND LUPUS NEPHRITIS

TW Du Clos… - US Patent 20,110,152,202, 2011 - freepatentsonline.com
The present invention relates to the use of a mutant CRP molecule in which tyrosine 175 is replaced
by leucine (Y175L CRP) or the leucine 176 is replaced by glutamic acid (L176E CRP) for the
treatment of various disease states and conditions associated with SLE, including lupus ...
Related articles - Cached

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

© 2010-2024 中国: LetPub上海分公司    网站备案号：沪ICP备10217908号-1    沪公网安备号：31010402006960

增值电信业务经营许可证：沪B2-20211595

礼翰商务信息咨询（上海）有限公司      办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室

United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451